• Je něco špatně v tomto záznamu ?

Strategies to optimize siRNA delivery to hepatocellular carcinoma cells

L. Scarabel, F. Perrone, M. Garziera, R. Farra, M. Grassi, F. Musiani, C. Russo Spena, B. Salis, L. De Stefano, G. Toffoli, F. Rizzolio, F. Tonon, M. Abrami, G. Chiarappa, G. Pozzato, G. Forte, G. Grassi, B. Dapas,

. 2017 ; 14 (6) : 797-810. [pub] 20170217

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030984

INTRODUCTION: hepatocellular carcinoma (hcc) is the predominant form of primary liver cancer and the second leading cause of cancer-associated mortality worldwide. available therapies for hcc have limited efficacy due to often late diagnosis and the general resistance of hcc to anti-cancer agents; therefore, the development of novel therapeutics is urgently required. small-interfering rna (sirna) molecules are short, double-stranded rnas that specifically recognize and bind the mrna of a target gene to inhibit gene expression. despite the great therapeutic potential of sirnas towards many human tumors including hcc, their use is limited by suboptimal delivery. Areas covered: In this review, we outline the current data regarding the therapeutic potential of siRNAs in HCC and describe the development of effective siRNA delivery systems. We detail the key problems associated with siRNA delivery and discuss the possible solutions. Finally, we provide examples of the various siRNA delivery strategies that have been employed in animal models of HCC and in human patients enrolled in clinical trials. Expert opinion: Despite the existing difficulties in siRNA delivery for HCC, the increasing scientific attention and breakthrough studies in this field is facilitating the design of novel and efficient technical solutions that may soon find practical applications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030984
003      
CZ-PrNML
005      
20171127165243.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/17425247.2017.1292247 $2 doi
035    __
$a (PubMed)28266887
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Scarabel, Lucia $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
245    10
$a Strategies to optimize siRNA delivery to hepatocellular carcinoma cells / $c L. Scarabel, F. Perrone, M. Garziera, R. Farra, M. Grassi, F. Musiani, C. Russo Spena, B. Salis, L. De Stefano, G. Toffoli, F. Rizzolio, F. Tonon, M. Abrami, G. Chiarappa, G. Pozzato, G. Forte, G. Grassi, B. Dapas,
520    9_
$a INTRODUCTION: hepatocellular carcinoma (hcc) is the predominant form of primary liver cancer and the second leading cause of cancer-associated mortality worldwide. available therapies for hcc have limited efficacy due to often late diagnosis and the general resistance of hcc to anti-cancer agents; therefore, the development of novel therapeutics is urgently required. small-interfering rna (sirna) molecules are short, double-stranded rnas that specifically recognize and bind the mrna of a target gene to inhibit gene expression. despite the great therapeutic potential of sirnas towards many human tumors including hcc, their use is limited by suboptimal delivery. Areas covered: In this review, we outline the current data regarding the therapeutic potential of siRNAs in HCC and describe the development of effective siRNA delivery systems. We detail the key problems associated with siRNA delivery and discuss the possible solutions. Finally, we provide examples of the various siRNA delivery strategies that have been employed in animal models of HCC and in human patients enrolled in clinical trials. Expert opinion: Despite the existing difficulties in siRNA delivery for HCC, the increasing scientific attention and breakthrough studies in this field is facilitating the design of novel and efficient technical solutions that may soon find practical applications.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a hepatocelulární karcinom $x genetika $x terapie $7 D006528
650    _2
$a buněčné linie $7 D002460
650    _2
$a lidé $7 D006801
650    _2
$a nádory jater $x genetika $x terapie $7 D008113
650    _2
$a malá interferující RNA $x aplikace a dávkování $7 D034741
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Perrone, Francesca $u b Department of Life Sciences, Cattinara University Hospital , University of Trieste , Trieste , Italy.
700    1_
$a Garziera, Marica $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
700    1_
$a Farra, Rossella $u c Department of Engineering and Architecture , University of Trieste , Trieste , Italy.
700    1_
$a Grassi, Mario $u c Department of Engineering and Architecture , University of Trieste , Trieste , Italy.
700    1_
$a Musiani, Francesco $u d Laboratory of Bioinorganic Chemistry, Department of Pharmacy and Biotechnology , University of Bologna , Bologna , Italy.
700    1_
$a Russo Spena, Concetta $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
700    1_
$a Salis, Barbara $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
700    1_
$a De Stefano, Lucia $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
700    1_
$a Toffoli, Giuseppe $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
700    1_
$a Rizzolio, Flavio $u a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
700    1_
$a Tonon, Federica $u c Department of Engineering and Architecture , University of Trieste , Trieste , Italy.
700    1_
$a Abrami, Michela $u b Department of Life Sciences, Cattinara University Hospital , University of Trieste , Trieste , Italy. $7 gn_A_00000757
700    1_
$a Chiarappa, Gianluca $u c Department of Engineering and Architecture , University of Trieste , Trieste , Italy.
700    1_
$a Pozzato, Gabriele $u e Department of 'Scienze Mediche, Chirurgiche e della Salute' , Cattinara University Hospital, University of Trieste , Trieste , Italy.
700    1_
$a Forte, Giancarlo $u f Center for Translational Medicine, International Clinical Research Center , St. Anne's University Hospital , Brno , Czech Republic.
700    1_
$a Grassi, Gabriele $u b Department of Life Sciences, Cattinara University Hospital , University of Trieste , Trieste , Italy. e Department of 'Scienze Mediche, Chirurgiche e della Salute' , Cattinara University Hospital, University of Trieste , Trieste , Italy.
700    1_
$a Dapas, Barbara $u b Department of Life Sciences, Cattinara University Hospital , University of Trieste , Trieste , Italy.
773    0_
$w MED00193514 $t Expert opinion on drug delivery $x 1744-7593 $g Roč. 14, č. 6 (2017), s. 797-810
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28266887 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171127165410 $b ABA008
999    __
$a ok $b bmc $g 1254577 $s 992011
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 14 $c 6 $d 797-810 $e 20170217 $i 1744-7593 $m Expert opinion on drug delivery $n Expert Opin Drug Deliv $x MED00193514
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace